Clinical Trials Market size to exceed USD 144.4 billion by 2035

The global clinical trials market size accounted for USD 66.3 billion in 2025 and is expected to grow from USD 70.7 billion in 2026 to USD 144.4 billion in 2035, growing at a CAGR of 8.3%, as per the latest report published by Global Market Insights, Inc.

Increasing Prevalence of Chronic Diseases Across the Globe

The increasing prevalence of chronic diseases worldwide is significantly driving demand for advanced healthcare services, clinical research, and specialized treatment solutions. Conditions such as cancer, cardiovascular diseases, diabetes, respiratory disorders, and neurological illnesses continue to rise due to aging populations, sedentary lifestyles, environmental factors, and changing dietary habits. The growing burden of long-term illnesses has increased the need for continuous disease monitoring, innovative therapies, and efficient healthcare management systems.

Growing Demand for Outsourcing Clinical Trials to CROs

The growing demand for outsourcing clinical trials to contract research organizations (CROs) is becoming a major factor supporting the expansion of the global clinical research industry. Pharmaceutical, biotechnology, and medical device companies are increasingly partnering with CROs to improve operational efficiency, reduce development timelines, and optimize overall research costs. CROs offer specialized expertise in clinical trial management, regulatory compliance, patient recruitment, data analytics, and monitoring services, enabling sponsors to focus on core research and commercialization activities.

Lack of Standard-of-Care Coverage from Insurance Providers

Limited standard-of-care coverage from insurance providers remains a significant challenge affecting patient access to advanced healthcare treatments and clinical research participation. Many innovative therapies, specialized diagnostics, and experimental treatment procedures involve high costs that may not be fully covered under traditional insurance policies. This financial burden can restrict patient enrollment in clinical studies and reduce access to advanced medical care, particularly among economically vulnerable populations.

Browse key industry insights spread across 174 pages with 176 market data tables and figures from the report, Clinical Trials Market “By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional Study, Observational Study, Expanded Access Study), By Therapeutic Area (Autoimmune Disease, Oncology, Cardiology, Infectious Disease, Dermatology, Ophthalmology, Neurology, Hematology, Other Therapeutic Areas), and By Service Type (Outsourcing Service, In-House Service), Growth Forecast.” in detail, along with the table of contents:   https://www.gminsights.com/industry-analysis/clinical-trials-market

Phase III Segment to Gain Traction

The phase III segment led the global clinical trials market and accounted for USD 32.1 billion in 2025. This segment maintained its dominant position due to its critical role in validating the safety, efficacy, and therapeutic effectiveness of investigational drugs before regulatory approval. Phase III studies are generally conducted on a large scale and involve thousands of participants across multiple geographic regions and clinical sites.

Rising Adoption of Outsourcing Services

The clinical trials market from outsourcing services segment held a 64.4% share in 2025. Pharmaceutical, biotechnology, and medical device companies are increasingly outsourcing clinical trial operations to contract research organizations to improve efficiency, reduce operational costs, and accelerate development timelines. The growing complexity of clinical studies has significantly increased the need for specialized outsourcing services that can manage regulatory compliance, patient recruitment, trial monitoring, and data management more effectively.

North America to Propel Market Growth

North America clinical trials market held a 50.7% share in 2025. The region maintained its leadership position due to the strong presence of major pharmaceutical and biotechnology companies, advanced research infrastructure, and significant investments in drug development activities. North America also benefits from a well-established regulatory environment and a large network of contract research organizations that support efficient and high-quality clinical trial execution.

Key companies operating in the clinical trials industry include Cadiya, Celerion, Charles River Laboratories, ClinChoice, ICON plc, IQVIA Holdings, Labcorp Holdings, Medpace, Parexel International Corporation, Pharmaceutical Product Development, Qserve, SGS SA, Syneos Health, The Emmes Company, Veeda, Worldwide Clinical Trials, and WuXi AppTec.

Companies operating in the clinical trials market are focusing on strategic partnerships, mergers, and acquisitions to expand service capabilities and strengthen their global presence. Leading CROs are investing heavily in advanced technologies such as artificial intelligence, decentralized clinical trial platforms, data analytics, and remote patient monitoring solutions to improve trial efficiency and accelerate study timelines. Market participants are also expanding their regional networks and establishing specialized research centers to enhance patient recruitment and regulatory support across international markets.

In April 2026, US Food and Drug Administration FDA launched a pilot program to implement real- time clinical trials. It announced that two proof of concept trials had been successfully initiated by AstraZeneca and Amgen, which reported endpoints and data signals to the agency in real time.